



<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>				Docket No. <b>13257-00040 (UMD-0096)</b>	
Applicant(s): <b>Ron et al.</b>					
Application No. <b>09/830,176</b>	Filing Date <b>April 23, 2001</b>	Examiner <b>Joseph T. Weitach</b>	Customer No. <b>46046</b>	Group Art Unit <b>1632</b>	Confirmation No. <b>2969</b>
Invention: <b>MYELOID PRECURSOR CELL USEFUL FOR GENE THERAPY AND FOR MODULATION OF IMMUNE RESPONSES</b>					
<b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	5 -	20 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	2 -	6 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>50-1619</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ <i>Signature</i>			Dated: <b>September 6, 2005</b>		
<b>Jane Massey Licata</b> <b>Reg. No. 32,257</b>  <b>Licata &amp; Tyrrell P.C.</b> <b>66 E. Main Street</b> <b>Marlton, NJ 08053</b>			I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on  _____ <i>(Date)</i>		
cc:			<i>Signature of Person Mailing Correspondence</i>		
			<i>Typed or Printed Name of Person Mailing Correspondence</i>		

09-07-05

AF  
JAW



RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 13257-00040 (UMD-0096)  
Inventors: Ron et al.  
Serial No.: 09/830,176  
Filing Date: April 23, 2001  
Examiner: Woitach, Joseph T.  
Customer No.: 46046  
Group Art Unit: 1632  
Confirmation No.: 2969  
Title: A Myeloid Precursor Cell Useful for Gene  
Therapy and for Modulation of Immune  
Responses

"Express Mail" Label No. EV794824816US  
Date of Deposit September 6, 2005

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Commissioner for Patents, Mail Stop AF,  
P. O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents  
Mail Stop AF  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Reply Under 37 C.F.R. § 1.116

This is a reply to the Office action mailed June 3, 2005 setting a three (3) month statutory period for reply. Please enter the following remarks and amendments into the record.

**Amendments to the Claims** are reflected in the listing of claims which begin on page 3 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.